Both CCL5 and CCL2 have been shown to enhance the migratory abilities of prostate cancer cells ultimately contributing to their migration to other parts of the body including to the bone, the most common site of prostate cancer metastasis. This evidence concerns the gene CCL5 and prostate carcinoma.